| Hu, Chaur-Jong |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT04097652: Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | 1 | 9 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Ischemic Stroke | 12/23 | 12/25 | | |
| Chen, Wei |
NCT06467513: To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications |
|
|
| Recruiting | 4 | 102 | RoW | Esketamine hydrochloride injection, 0.9% sodium chloride injection | Zhang XIao Mei | Heart Diseases, Heart Valve Diseases | 05/25 | 05/25 | | |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
NCT06597201: Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition. |
|
|
| Recruiting | 4 | 400 | RoW | amino acid (15) peritoneal dialysis solution, glucose peritoneal dialysis solution | Chengdu Qingshan Likang Pharmaceutical Co., Ltd | End Stage Renal Disease (ESRD) | 06/25 | 06/25 | | |
NCT05721404: Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis |
|
|
| Recruiting | 4 | 194 | RoW | Icodextrin Peritoneal Dialysis Solution, Hypertonic Dextrose solution | First Affiliated Hospital, Sun Yat-Sen University, Baxter Healthcare Corporation | Peritoneal Dialysis | 04/25 | 12/25 | | |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
NCT06720233: Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis |
|
|
| Completed | 3 | 37 | RoW | SAL-0951 tablets, SAL-0951 group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 10/24 | 10/24 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT06720025: Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis |
|
|
| Completed | 3 | 100 | RoW | SAL-0951 tablets, SAL-0951 group, rHuEPO injection, rHuEPO group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 06/24 | 06/24 | | |
| Recruiting | 3 | 450 | Europe, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Perennial Allergic Rhinitis (PAR) | 05/25 | 05/26 | | |
NCT04370925: Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis |
|
|
| Recruiting | 3 | 688 | RoW | Radical colectomy, HIPEC, Systemic chemotherapy | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan, Shantou Central Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, ZhuHai Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Hospital, Beijing Cancer Hospital, Peking University People's Hospital, Fudan University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Cancer Hospital, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Wuhan University, Sichuan Provincial People's Hospital, West China Hospital, The People's Hospital of Leshan, People’s Hospital of Deyang City, Hebei Medical University Fourth Hospital, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital Of Southwest Medical University, The Affiliated Hospital of Xuzhou Medical University, People's Hospital of Guangxi, The Third People's Hospital of Chengdu, The Affiliated Tumor Hospital of Guangxi Medical University | Colorectal Cancer | 04/24 | 04/26 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Recruiting | 2/3 | 230 | Canada, US | MN-166, ibudilast, placebo | MediciNova | Amyotrophic Lateral Sclerosis | 12/25 | 12/26 | | |
NCT06470191: A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. |
|
|
| Recruiting | 2/3 | 216 | RoW | B007, Cyclosporin Capsules | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Primary Membranous Nephropathy | 12/26 | 12/26 | | |
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease |
|
|
| Recruiting | 2a | 60 | RoW | 50561 high dose, 50561 low dose, Placebo | Beijing Joekai Biotechnology LLC | Alzheimer's Disease | 05/24 | 06/24 | | |
NCT06435182: Study of OT202 in Treating Moderate to Severe Dry Eye |
|
|
| Completed | 2 | 213 | RoW | OT202 conc 0.5%, Investigational product, OT202 conc 0.1%, Placebo | Ocumension Therapeutics (Shanghai) Co., Ltd | Dry Eye | 01/24 | 01/24 | | |
NCT05810961: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) |
|
|
| Terminated | 2 | 8 | RoW | efgartigimod IV, placebo | argenx, Zai Lab Pty. Ltd. | Membranous Nephropathy | 08/24 | 08/24 | | |
NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013) |
|
|
| Recruiting | 2 | 60 | RoW | efgartigimod IV, Placebo | argenx, Zai Lab (Shanghai) Co., Ltd. | Lupus Nephritis | 07/25 | 09/25 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
NICRRBTC, NCT06699459: Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC |
|
|
| Not yet recruiting | 2 | 76 | RoW | Irinotecan Liposome, Irinotecan Liposome+LV/5-FU, Capecitabine | Sir Run Run Shaw Hospital, Zhejiang Cancer Hospital, RenJi Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Fujian Provincial Hospital, Ningbo No. 1 Hospital, Shaoxing People's Hospital, Southern Medical University, China, First Affiliated Hospital, Sun Yat-Sen University | Biliary Tract Carcinoma | 11/26 | 11/26 | | |
NCT06760182: Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQH2722 injection, TQH2722 Placebo | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Seasonal Allergic Rhinitis | 06/25 | 08/25 | | |
MAGIC, NCT05053802: Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial |
|
|
| Recruiting | 2 | 146 | RoW | Microwave ablation plus Camrelizumab, Microwave ablation | Shanghai Pulmonary Hospital, Shanghai, China | Multiple Primary Lung Cancer | 09/25 | 09/27 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
NCT06474416: A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis |
|
|
| Recruiting | 1 | 16 | RoW | BD111 Injection (Investigative New Drug), BD111 Lentivirus-like particles, HSV-1-erasing lentiviral particles, HELP, Triple-drugs therapy of HSV-1 stromal keratitis, Ganciclovir Ophthalmic Gel, Valacyclovir Hydrochloride Tablets, Prednisolone Acetate Ophthalmic Suspension | Shanghai BDgene Co., Ltd. | Herpes Simplex Virus Type I Stromal Keratitis | 09/25 | 09/25 | | |
NCT05633459: A Study Evaluating the Safety and Tolerability of QRL-201 in ALS |
|
|
| Recruiting | 1 | 64 | Europe, Canada | Multiple ascending doses of QRL-201, Multiple ascending doses of Placebo, QRL-201, Placebo | QurAlis Corporation | Amyotrophic Lateral Sclerosis | 08/26 | 08/26 | | |
| Recruiting | N/A | 5000 | RoW | No Intervention: Observational Cohort | First Affiliated Hospital, Sun Yat-Sen University | Lupus Nephritis (LN) | 12/50 | 12/50 | | |
| Terminated | N/A | 1706 | RoW | SpO2 directed oxygen therapy | Wuhan Union Hospital, China, Wu Jieping Medical Foundation | Critical Illness | 05/22 | 05/22 | | |
NCT05311462: An Observational Cohort Study to Obese Patients With Weight Cycling |
|
|
| Active, not recruiting | N/A | 180 | RoW | | Peking Union Medical College Hospital | Weight Cycling, Obesity | 01/25 | 12/28 | | |
NCT05570435: Efficacy of Milk Product Supplemented With Bioactives in Lowering Post Meal Glucose Response |
|
|
| Completed | N/A | 31 | RoW | Blood collection | Société des Produits Nestlé (SPN), Peking Union Medical College Hospital | Healthy, PreDiabetes, Adult, Asian | 03/23 | 03/23 | | |
NCT05857917: Virtual Reality for for Pain and Anxiety Distraction Strategy on Peritoneal Catheter Insertion |
|
|
| Recruiting | N/A | 70 | RoW | Virtual Reality | First Affiliated Hospital, Sun Yat-Sen University | Renal Function Disorder | 10/23 | 10/23 | | |
NCT05859165: To Evaluate Clinical Efficacy and Safety of Diabetes-Specific Formula (Nutren Diabetes) |
|
|
| Recruiting | N/A | 250 | RoW | Nutren Diabetes, Fresubin Diabetes | Société des Produits Nestlé (SPN), Nestle Health Science | Diabetes Mellitus | 12/24 | 06/25 | | |
| Recruiting | N/A | 70 | US | Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List | Ira Winer | Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Gestational Trophoblastic Disease | 05/26 | 05/27 | | |
NCT05651321: Studies on the Impact of Taste-aware Intelligent Analysis of Oral Nutritional Supplements |
|
|
| Recruiting | N/A | 108 | RoW | Samples materials of basic taste stimuli and enteral nutrition preparations | Peking Union Medical College Hospital | Cancer- and Cancer Treatment-Related Conditions, Stroke | 06/24 | 12/24 | | |
WHIP, NCT06545721: Weight Cycling on Hyperandrogenemia and Insulin Resistance in Polycystic Ovary Syndrome |
|
|
| Not yet recruiting | N/A | 425 | RoW | Adjusting dietary structure + exercise + behavioral intervention | Peking Union Medical College Hospital | Polycystic Ovary Syndrome | 08/25 | 08/26 | | |
| Active, not recruiting | N/A | 11737 | US | | Tulane University, National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS) | Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Hypertension | 11/29 | 11/29 | | |
NCT05190848: Correlation of Microbiome and Metabonomics With IgA Nephropathy |
|
|
| Recruiting | N/A | 600 | RoW | | Guangdong Provincial People's Hospital | IgA Nephropathy | 12/24 | 12/24 | | |
NCT06793475: Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease |
|
|
| Recruiting | N/A | 20 | RoW | anti-BCMA/GPRC5D bispecific CAR-T, Apornemin, Carfilzomib, Thalidomide, Dexamethasone | Institute of Hematology & Blood Diseases Hospital, China | Extramedullary Multiple Myeloma | 06/26 | 12/26 | | |
NCT04212494: Thrombus Aspiration in STEMI Patients With High Thrombus Burden |
|
|
| Recruiting | N/A | 3838 | RoW | Thrombus aspiration, PCI Alone | Guangdong Provincial People's Hospital, Zhongshan People's Hospital, Guangdong, China, Kaiping Central Hospital, The Second Affiliated Hospital of Shantou University Medical College, The Third Xiangya Hospital of Central South University, Sihui City People's Hospital, Shenzhen Baoan District Shiyan People's Hospital, People's Hospital of Nanxiong County, Yuebei People's Hospital, Weifang Medical University, Wuzhou Gongren Hospital, Dafeng Hospital of Chaoyang District in Shantou City, Shenzhen Baoan People's Hospital, Dongguan People's Hospital, Yangchun People's Hospital, Taishan People's Hospital, The Second People's Hospital of Foshan, Guangzhou Hospital of integrated Traditional and West Medicine, Guangning People's Hospital, Foshan Sanshui District People's Hospital, Qingyuan People's Hospital, Luhe County People's Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The Fourth People's Hospital of Chenzhou, People's Hospital of Dapu County, Shenzhen People's Hospital, Heyuan people's Hospital, Huaiji People's Hospital, People's Hospital of Yingde City, Qingyuan Hospital of Traditional Chinese Medicine Affiliated To Guangzhou University of Traditional Chinese Medicine, Zhongshan Hospital Of Traditional Chinese Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Lianzhou People's Hospital, Lianping Xian Ren Ming Yi Yuan, Guangxi Zhuang Autonomous Region Nationalities Hospital, Liuzhou Municipal Liutie Central Hospital, Chen Zhou 3RD People's Hospital, Longgang District Central Hospital of Shenzhen, The Affiliated Shunde Hospital of Jinan University, Shenzhen Longhua District Central Hospital, Shantou Central Hospital, Tongxiang First People's Hospital, Bobai County People's Hospital, Guangxi, Meizhou Traditional Chinese Medicine Hospital, The Third Affiliated Hospital of Sun Yat-Sen University, Yuedong Hospital, Shenzhen Third People's Hospital, Yangjiang People's Hospital, Jiangmen Central Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, The First People's Hospital of Kashgar Erea, First People's Hospital of Foshan, Zhaoqing Gaoyao People's Hospital, People's Hospital of Nanhai District, Foshan, The Second Affiliated Hospital of Dalian Medical University, Nanning Second People's Hospital, The Second People's Hospital of Nanhai District of Foshan, Shangyou People's Hospital | ST-segment Elevation Myocardial Infarction (STEMI) | 08/25 | 02/26 | | |
NCT05754866: Transbronchial Lung Cryobiopsy in Undiagnosed Acute Respiratory Failure |
|
|
| Recruiting | N/A | 100 | RoW | Transbronchial lung cryobiopsy, Transbronchial lung biopsy | China-Japan Friendship Hospital | Acute Respiratory Failure, Acute Respiratory Distress Syndrome | 11/25 | 11/25 | | |
NCT05188885: A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases |
|
|
| Recruiting | N/A | 90000 | RoW | | Guangdong Provincial People's Hospital | Chronic Kidney Disease | 12/26 | 12/28 | | |
| Choi, Seong Ho |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Active, not recruiting | 3 | 1083 | Canada, US, RoW | Simufilam, PTI-125, Placebo | Cassava Sciences, Inc., Premier Research Group plc | Alzheimer Disease | 05/25 | 05/25 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Recruiting | 2 | 282 | Europe, Canada, US, RoW | GSK4527226, Placebo | GlaxoSmithKline, Alector Inc. | Alzheimer's Disease | 12/26 | 02/29 | | |
NCT05262452: Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer |
|
|
| Recruiting | N/A | 60 | RoW | ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system, FOLFIRINOX regimen | Seoul National University Hospital, Focused Ultrasound Foundation, Synex Consulting Ltd | Pancreatic Cancer Non-resectable, Chemotherapy Effect, Ultrasound Therapy | 03/23 | 12/24 | | |
SUPERBRAIN, NCT05023057: Multidomain Interventions Via Face-to-face and Video Communication Platforms in Mild Cognitive Impairment |
|
|
| Completed | N/A | 300 | RoW | Multidomain intervention | Inha University Hospital | Mild Cognitive Impairment | 03/23 | 03/23 | | |
| Recruiting | N/A | 100 | RoW | Multidomain intervention, multidomain cognitive intervention | Inha University Hospital | Mild Cognitive Impairment | 11/23 | 12/23 | | |
| Recruiting | N/A | 94 | RoW | Chewing gum | Inha University Hospital, Bobath Memorial Hospital | Cognitive Dysfunction | 12/23 | 12/23 | | |
| Gu, Ping |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT03550183: Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease |
|
|
| Enrolling by invitation | 1 | 20 | RoW | mesenchymal stem cells | Hebei Newtherapy BIo-Pharma technology Co., Ltd. | Parkinson's Disease | 10/22 | 12/22 | | |
| Macfarlane, Stephen |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Completed | 2/3 | 300 | Europe, Canada, RoW | ANAVEX2-73, Blarcamesine | Anavex Life Sciences Corp., Anavex Australia Pty Ltd., Anavex Germany GmbH | Alzheimer Disease | 06/24 | 06/24 | | |
| Wu, Mai-Szu |
NCT04543812: PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD |
|
|
| Completed | 3 | 141 | RoW | Ferric citrate, Placebo | Panion & BF Biotech Inc. | Anemia of Chronic Kidney Disease | 10/22 | 12/22 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
| Recruiting | 3 | 685 | Europe, Canada, US, RoW | Renal Autologous Cell Therapy (REACT), Sham Comparator | Prokidney, Iqvia Pty Ltd, PPD | Type 2 Diabetes Mellitus, Chronic Kidney Diseases | 02/27 | 02/27 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT02933827: Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease |
|
|
| Completed | 1/2 | 39 | RoW | ELIXCYTE | UnicoCell Biomed CO. LTD, Protech Pharmaservices Corporation (PPC) | Moderate to Severe Chronic Kidney Disease | 04/19 | 06/23 | | |
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy |
|
|
| Active, not recruiting | 1 | 16 | Europe, Japan, US, RoW | Mezagitamab, TAK-079 | Takeda | Kidney Disease, Glomerulonephritis | 03/26 | 03/26 | | |
| Lee, Kang-Yun |
| Completed | 3 | 397 | Europe, Canada, Japan, US, RoW | GSK3511294, Depemokimab, Placebo | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 04/24 | 04/24 | | |
|
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) |
|
|
| Active, not recruiting | 3 | 641 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 05/25 | 05/25 | | |
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2/3 | 950 | Canada, US, RoW | fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo | Regeneron Pharmaceuticals | Non-small Cell Lung Cancer | 01/30 | 12/31 | | |
R3767-ONC-2235, NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2/3 | 850 | Canada, US, RoW | fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Placebo | Regeneron Pharmaceuticals | Advanced Non-Small Cell Lung Cancer | 03/30 | 02/32 | | |
|
NCT05008965: Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma |
|
|
| Recruiting | 2 | 100 | RoW | FB825, Placebo | Oneness Biotech Co., Ltd., Microbio Shanghai Co., Ltd. | Allergic Asthma | 06/24 | 06/24 | | |
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 115 | RoW | EP0057, Olaparib tablets | Ellipses Pharma | Gastric Cancer, Small-cell Lung Cancer | 08/24 | 12/24 | | |
NCT06415487: ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) |
|
|
| Recruiting | 1 | 30 | US, RoW | Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab | Acepodia Biotech, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 12/26 | 03/27 | | |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
NCT04909034: A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer |
|
|
| Completed | N/A | 15 | RoW | MS-20, Chemo young, Placebo | Microbio Co Ltd | NSCLC Stage IIIB~IV | 10/24 | 11/24 | | |
| Recruiting | N/A | 550 | RoW | | National Health Research Institutes, Taiwan | Non-small-cell Lung Cancer | 12/25 | 12/30 | | |
| Rewerska, Barbara |
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
|
|
| Active, not recruiting | 3 | 1083 | Europe, Canada, US, RoW | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 12/24 | 02/25 | | |
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (). |
|
|
| Active, not recruiting | 3 | 837 | Europe, RoW | CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant | Chiesi Farmaceutici S.p.A. | Asthma | 07/25 | 09/25 | | |
| Suspended | 3 | 675 | Europe, Canada, US, RoW | Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo | Anji Pharma | Diabetes Mellitus, Type 2 | 12/23 | 06/24 | | |
SCALP2, NCT05914805: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss |
|
|
| Recruiting | 3 | 726 | Europe, US | Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle | Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research | Alopecia, Androgenetic | 08/24 | 03/25 | | |
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS) | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 05/25 | 09/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 310 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
TRITON, NCT04320342 / 2020-002389-16: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD |
|
|
| Active, not recruiting | 3 | 3433 | Europe, Canada, US, RoW | Beclomethasone Dipropionate, BDP, Glycopyrronium Bromide, glycopyrrolate, GB, Formoterol Fumarate, FF | Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A. | COPD, COPD Exacerbation | 01/26 | 01/26 | | |
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy |
|
|
| Recruiting | 2 | 450 | Europe, Canada, Japan, US, RoW | LY3848575, Placebo | Eli Lilly and Company | Neuropathic Pain, Distal Sensory Polyneuropathy | 06/26 | 09/26 | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 236 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
| Lee, Woan-Ruoh |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 236 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
NCT05719649: The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial |
|
|
| Not yet recruiting | N/A | 72 | NA | Lactic acid bacteria NTU 101, Placebo | SunWay Biotech Co., LTD. | Atopic Dermatitis, Atopic Dermatitis Eczema | 05/23 | 05/23 | | |
| Kawashima, Kayoko |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 11/25 | 10/26 | | |
| Boutoleau-Bretonierre, Claire |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Kolinek, Joanna |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 236 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
| Borzova, Claudia Vodickova |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
